## Executive summary Under the supplied governing law, this is a high-risk controller/self-dealing acquisition case. The board should assume that the transaction will be reviewed under **entire fairness**, not business-judgment review, and that the defendants will bear a significant burden. The key conclusions are: 1. **Elena Voss is likely a controller**, or at minimum a heavily interested party whose conduct makes controller status a close question. Her 34% block, founder/CEO/chair position, board nomination power, pre-commitment negotiations, public statements, and undisclosed side payment support actual control over the challenged transaction. 2. **The special committee and majority-of-the-minority vote likely do not restore business-judgment review.** The committee was formed after preliminary negotiations and public commitment, its independence and diligence are impaired, and the shareholder vote was not fully informed because of material omissions. 3. **The omissions were likely material**: the $8 million side payment, Peak Partners’ $12 million prior fee history, the earlier lower forecast, and the principal customer’s 90-day termination right. 4. **Fair dealing is likely deficient.** The transaction appears to have been driven by an interested controller, with a compromised committee, conflicted financial adviser, limited market check, and inadequate disclosure. 5. **Fair price is genuinely contested.** $190 million was within Peak’s stated range, but Peak was conflicted, the data used was arguably incomplete, and the post-closing customer termination and 70% write-down strongly support a lower valuation. At trial, valuation will be central. 6. **Elena is likely personally exposed**, including for loyalty, disclosure, and possibly bad-faith claims, as well as disgorgement of the $8 million improper personal benefit. Exculpation does not protect her from loyalty, bad faith, or improper personal benefit claims. 7. **The directors’ exposure depends on bad faith versus mere carelessness.** If their failures are merely duty-of-care failures, the exculpation clause may shield them from monetary liability. But if they knowingly approved material omissions or consciously disregarded red flags, exculpation may not protect them. 8. **Peak Partners has meaningful aiding-and-abetting exposure**, although proving “knowing” participation will require discovery. Its $12 million prior relationship with Elena, nondisclosure of the fee amount, and reliance on flawed projections create a strong factual record for plaintiffs. 9. **A motion to dismiss will likely fail on the core entire-fairness claims**, though some pure duty-of-care claims against disinterested directors may be dismissed or narrowed under the exculpation clause. 10. **Discovery will be broad and invasive**, covering controller status, committee independence, Peak’s conflicts, the data room, forecasts, customer concentration, market checks, proxy preparation, and valuation. 11. **Settlement exposure is likely in the high seven figures to low eight figures, with a tail into the mid-eight or nine figures if valuation shows substantial overpayment.** The $133 million write-down is a large litigation number, but not automatically a damages number. 12. **The board should immediately form an independent special litigation committee**, retain independent counsel and advisers, preserve documents, investigate, and then decide between defense and settlement. Given the entire-fairness burden and material omissions, an early settlement after a focused investigation is a realistic and likely prudent path, but only after independent valuation and litigation assessment. --- # 1. Whether Elena should be treated as Asterix’s controller The governing law defines a controller as a shareholder who owns **more than 50% of voting power** or exercises **actual control over the board or the challenged transaction**. Elena owns only **34%** of voting stock, so she does not qualify on the ownership prong. The question is whether she exercised actual control over the board or the NovaSense transaction. ## Facts supporting controller status The record strongly supports a finding that Elena had actual control over the challenged transaction, even if not over the whole company: - She was **founder, CEO, and board chair**. - She **proposed the acquisition**. - She **negotiated a preliminary term sheet with NovaSense before the special committee was formed**. - She publicly stated that the companies were “nearing a transformative combination” before the committee existed. - She told the committee that delay could allow a competitor to acquire NovaSense, pressuring the committee. - She owned **22% of NovaSense** through an investment vehicle. - She had an **undisclosed $8 million side payment** if NovaSense sold for more than $150 million. - Six of the nine directors were originally nominated by her, suggesting significant board influence. - The board included current executives who are naturally aligned with management. The most important fact is that she **initiated and preliminarily negotiated the transaction before an independent committee existed**. That is classic evidence of actual control over the challenged transaction. ## Possible counterarguments A court could find that she was not a controller because: - She owned less than 50%. - She did not have formal voting control. - A special committee was formed. - A majority of disinterested shareholders approved the transaction. But those facts do not erase her role in initiating and framing the deal before any meaningful independent process began. ## Likely result The board should assume that a court or the parties at discovery stage would treat Elena as either: 1. **A controller under the “actual control over the challenged transaction” prong**, or 2. At least a **dominant interested party** whose conduct makes controller analysis the safer framework. Even if a court ultimately rejects formal controller status, the case would still be analyzed as a self-dealing transaction by an interested fiduciary, and the cleansing protections would still need to be “fully informed” and effective. The practical result would likely remain **entire fairness**. --- # 2. Whether the special committee and shareholder vote alter the standard of review ## If Elena is a controller Under the governing law, a controller’s self-dealing transaction receives business-judgment review only if, **from the outset**, the transaction is conditioned on both: 1. Approval by an **independent, fully empowered committee** that satisfies its duty of care; and 2. An **informed and uncoerced majority-of-the-minority shareholder vote**. Here, neither protection is strong enough to trigger business-judgment review. ## The special committee was not “from the outset” The committee was formed **after** Elena had already: - Negotiated a preliminary term sheet with NovaSense; - Publicly described the companies as “nearing a transformative combination”; and - Told the committee that delay could allow a competitor to acquire NovaSense. That timing is highly problematic. The committee did not begin with a clean slate. It inherited a transaction that had already been initiated and publicly endorsed by the interested party. That does not automatically invalidate the committee, but it significantly weakens the argument that the transaction was conditioned on independent approval from the outset. ## The committee’s independence is impaired One of the three committee members chaired a charity receiving approximately **$500,000 annually** from Elena’s family foundation. That contribution represented about **8% of the charity’s annual budget**. Under the governing law, independence is compromised when material personal or financial ties create reasonable doubt about whether a director can act independently. Ordinary friendship alone is insufficient, but this is more than ordinary friendship. A chair-level relationship with a charity significantly funded by the interested fiduciary’s family foundation is a material financial tie that could create reasonable doubt. In addition, the committee retained **Peak Partners**, which had earned **$12 million from Elena and companies she controlled over the preceding five years**. Peak disclosed a “historical relationship” but did not disclose the amount. That creates a second layer of compromise: the committee’s financial adviser had a significant prior relationship with the interested party and did not make the material dimension of that relationship transparent. A committee that relies on a conflicted adviser and includes at least one potentially compromised member is weak ground for business-judgment review. ## The committee may not have satisfied its duty of care The committee’s process has several defects: - It did not include the earlier, lower NovaSense management forecast in board materials, even though that forecast was in the data room. - It discussed customer concentration generally but did not obtain or consider a sensitivity analysis for the principal customer. - That customer generated **61% of NovaSense revenue** and could terminate on **90 days’ notice**. - The committee considered contacting three alternative targets but did not conduct a broader market check. - It relied on a financial adviser with a significant prior relationship with Elena. - It approved a price within a broad range without apparent independent valuation discipline. These are serious duty-of-care concerns. They do not necessarily establish bad faith, but they undermine the claim that the committee was a fully informed, independent, and effective cleansing mechanism. ## The shareholder vote was not fully informed The vote was a majority of disinterested shares, and 54% favored the transaction. That is procedurally useful, but it is not enough if the vote was not **fully informed**. The proxy did not disclose: - The $8 million side payment; - The amount of Peak’s prior fees; - The earlier lower forecast; - The full details of the principal customer’s termination right. Each of those is likely material. Material omissions can defeat cleansing. Therefore, the shareholder vote likely does not satisfy the “informed” requirement. ## Could the standard still change if only one protection is effective? The governing law provides that if only one of the two protections is effective, entire fairness remains applicable, although the burden may shift. Here, that is possible but not very strong. For example, a court might find: - The committee was formally empowered and mostly independent, but the vote was not informed; or - The vote was a genuine majority of the minority, but the committee was compromised. In either case, the standard would still be entire fairness. The board may get some burden-shifting benefit, but it would still face an entire-fairness trial. Given the material omissions and committee defects, the more likely outcome is that **no cleansing benefit applies**, or only a limited one. ## If Elena is not a controller Even if the court finds Elena is not a controller, the governing law says that if an interested party is not a controller, business-judgment review is ordinarily restored by approval of a fully informed majority of disinterested directors or disinterested shareholders, unless the transaction is waste. Here: - There is no indication the transaction is waste. - But the disinterested shareholder vote was not fully informed. - The directors were not clearly fully disinterested or fully informed either. So even under the non-controller framework, business-judgment review is unlikely. ## Bottom line on standard of review The transaction should be analyzed under **entire fairness**. The defendants will bear the burden of proving fair dealing and fair price. The board should not assume that the committee and vote convert the case into business-judgment review. --- # 3. Effect of forming the committee after preliminary negotiations and public commitment This is one of the weakest facts for the defense. The governing law requires that, for a controller self-dealing transaction, the independent committee and majority-of-the-minority vote be conditions **from the outset**. Here, Elena had already: - Negotiated a preliminary term sheet; - Publicly stated that the companies were “nearing a transformative combination”; and - Pressured the committee by suggesting a competitor might otherwise acquire NovaSense. That sequence suggests the transaction was substantially set before the committee existed. The committee may have had formal authority to negotiate or reject, but it did not begin with an open process. It began after the interested party had already committed the company publicly and commercially to a deal path. This does not automatically make the deal unlawful. A committee formed after early discussions can sometimes still provide meaningful protection if it is truly independent, fully empowered, and actually re-negotiates the transaction. But here, the other facts make that argument harder: - The committee member had a material financial tie to Elena. - The adviser had a large prior relationship with Elena. - The committee did not conduct a broader market check. - It failed to confront the earlier lower forecast. - It failed to obtain a sensitivity analysis on the key customer. - The proxy omitted material facts. The practical effect is that the late committee formation will be used by plaintiffs to argue that the committee was a **post-hoc ratification device**, not a genuine independent check. --- # 4. Committee independence, authority, diligence, and good faith ## A. Independence The committee had three directors. One chaired a charity receiving about **$500,000 annually** from Elena’s family foundation, roughly **8% of the charity’s budget**. That is a fact question, but it is a strong one for plaintiffs. The relationship is not merely social. It involves an ongoing financial flow from the interested fiduciary’s family foundation to an organization the director chairs. A reasonable shareholder could question whether that director could negotiate against Elena’s interests with full independence. If the court finds that one committee member was not independent, the committee may fail the independence requirement. Even if the other two were independent, a three-person committee with one materially compromised member is vulnerable. The financial adviser also matters. Peak’s **$12 million prior fee relationship** with Elena and companies she controlled is a material conflict. Peak disclosed a “historical relationship” but did not disclose the amount. That likely makes Peak’s advice less credible and undermines the committee’s claim to independent, fully informed process. ## B. Authority The committee had formal authority to negotiate or reject the transaction. That is necessary, but not sufficient. The authority problem here is practical, not formal. The committee: - Did not conduct a broader market check; - Only considered contacting three alternative targets; - Accepted Elena’s warning that delay might allow a competitor to acquire NovaSense; - Did not appear to challenge the preliminary term sheet aggressively. A court might find that the committee had authority on paper but was practically constrained by the interested party’s early commitments and urgency narrative. ## C. Diligence The committee likely had duty-of-care problems. ### 1. Earlier lower forecast NovaSense’s earlier management forecast, prepared only two months before acquisition discussions, projected substantially slower growth. It was in the data room but not included in the committee’s board materials. A special committee reviewing a $190 million acquisition should have reviewed the data room carefully enough to understand material changes in management forecasts. If the committee did not review the earlier forecast, that is a diligence failure. If it reviewed it and did not disclose or explain the discrepancy, that is even worse. ### 2. Customer concentration NovaSense derived **61% of revenue** from one customer whose contract could be terminated on **90 days’ notice**. That is a major valuation risk. The committee discussed customer concentration generally but did not receive a sensitivity analysis showing the effect of losing that customer. A reasonably diligent committee would have requested: - Customer contract details; - Termination rights; - Renewal history; - Concentration revenue trends; - Sensitivity analysis for customer loss; and - Probability-weighted valuation scenarios. The failure to do so is a strong plaintiff fact. ### 3. Market check The committee considered contacting three alternative targets but did not conduct a broader market check. Elena told the committee that delay could allow a competitor to purchase NovaSense. If that warning was credible and verified, urgency could be defensible. But there is no indication the committee independently verified the competitive threat. It accepted the interested party’s urgency narrative. That supports a finding of inadequate process. ### 4. Reliance on Peak Peak’s range was **$175 million to $210 million**, and the committee approved $190 million. That may help the fair-price argument, but Peak was conflicted. Reliance on a conflicted adviser is less likely to satisfy the duty of care. ## D. Good faith Good faith is harder to establish for the defense. For **Elena**, good faith is difficult. She had: - A direct ownership interest in NovaSense; - An undisclosed side payment; - Early negotiations; - Public commitment; - Pressure on the committee. That conduct may support a bad-faith inference, especially if the side payment was concealed from the board, committee, or shareholders. For the **committee members**, good faith is more uncertain. If they did not know about the side payment, they may not have acted in bad faith personally. But they may have acted in bad faith if they: - Knew or should have known of material omissions; - Approved a proxy with material gaps; - Ignored Peak’s material prior fee relationship; - Failed to investigate obvious valuation risks; or - Consciously disregarded their duties. If their conduct is merely careless, exculpation may protect them. If it rises to conscious disregard, exculpation may not. --- # 5. Whether the omitted information was material A fact is material if a reasonable shareholder would consider it important in deciding how to vote. Material omissions may defeat cleansing. ## Likely material omissions ### 1. The $8 million side payment This is almost certainly material. It is a direct financial benefit to Elena, not shared proportionately with shareholders. It was contingent on the sale price. It created a personal incentive for her to approve a transaction above a certain price. It also goes to the heart of her loyalty and negotiating position. Even if the $8 million is small relative to the $190 million deal, it is qualitatively important. A reasonable shareholder would want to know that the CEO/founder would receive a personal carry distribution if the deal closed above $150 million. **Conclusion: Material.** ### 2. Peak’s prior $12 million fee relationship This is likely material, especially in the context of a special committee and controller self-dealing. Peak’s prior fees to Elena and companies she controlled over five years went to the independence and objectivity of the committee’s financial adviser. A reasonable shareholder would want to know the amount, not just that there was a “historical relationship.” The amount matters because $12 million is not trivial relative to the transaction and likely relative to Peak’s advisory fee. **Conclusion: Likely material.** ### 3. The earlier lower forecast This is likely material to fair price. A forecast prepared only two months before acquisition discussions that projected substantially slower growth is directly relevant to valuation. If management projections used in the committee materials were significantly more optimistic, shareholders would want to know why. The omission may also suggest cherry-picking of projections. **Conclusion: Material to price and process.** ### 4. Principal customer’s 90-day termination right This is likely material. A customer representing **61% of revenue** with a **90-day termination right** is a major risk. The post-closing termination and 70% write-down make that obvious in hindsight, but materiality is judged at the time of the vote and negotiation. Even then, a reasonable shareholder would consider it important. The proxy apparently did not disclose full details. General discussion of “customer concentration” is not enough when the contract termination right is this significant. **Conclusion: Material.** ### Possible additional material facts Plaintiffs may also argue that other facts were material, such as: - The committee member’s charity relationship; - The timing of the committee formation after preliminary negotiations; - The lack of a broader market check; - The competitive-threat narrative from Elena; - Elena’s 34% voting block and board nomination influence. The four listed omissions are the strongest. --- # 6. Fair dealing and fair price Entire fairness examines both **fair dealing** and **fair price**. Both must be proven by defendants if they bear the burden. ## A. Fair dealing Fair dealing looks at the process: how the transaction was initiated, negotiated, approved, and disclosed. Here, the fair-dealing record is poor for the defense. ### 1. Interested controller initiated the transaction Elena was interested in both sides: - As director/CEO of Asterix; - As a 22% owner of NovaSense; - And through the undisclosed $8 million side payment. That creates a high initial presumption of process concern. ### 2. Preliminary negotiations before independent committee The committee was formed after Elena negotiated a preliminary term sheet and publicly committed to the deal. That suggests the process was not genuinely open from the beginning. ### 3. Compromised committee and adviser The committee included at least one potentially compromised director and retained a conflicted financial adviser. That weakens the claim that the process was independent. ### 4. Inadequate market check The committee did not conduct a broader market check. It considered contacting three alternative targets but did not appear to pursue them. It relied on Elena’s competitive-threat warning. ### 5. Incomplete valuation input The committee materials omitted the earlier lower forecast and failed to address the principal customer’s termination risk with a sensitivity analysis. ### 6. Material disclosure omissions The proxy omitted: - The side payment; - Peak’s prior fee amount; - The earlier lower forecast; - Full details of the customer termination right. Those omissions go directly to the quality of the process and the integrity of the shareholder vote. ### Likely fair-dealing result Plaintiffs have a strong fair-dealing case. The defense can argue that a committee was formed, it had authority, a shareholder vote occurred, and the price was within the adviser’s range. But those arguments are weakened by the material omissions, conflicts, and timing. A court is likely to find that **fair dealing was not established** unless the defense can show the committee truly operated independently and the omitted facts were not material. Given the facts, that will be difficult. ## B. Fair price Fair price is more fact-intensive. The defense has some useful facts: - Peak concluded that $175 million to $210 million was financially fair. - The committee approved $190 million, within that range. - There was a shareholder vote in favor. But the defense has serious problems: - Peak was conflicted. - The range was based on projections that may have omitted the earlier lower forecast. - The committee did not obtain a sensitivity analysis on the key customer. - The key customer represented 61% of revenue and had a 90-day termination right. - Nine months after closing, that customer terminated. - Asterix wrote down 70% of the acquisition value. The post-closing write-down is not automatically proof that the price was unfair at closing. The customer termination risk may have been a business risk that should have been priced. But if the price did not adequately account for that risk, the write-down becomes powerful evidence of overpayment. At trial, the parties will likely present valuation evidence: - Discounted cash flow using the earlier forecast; - Probability-weighted DCF; - Comparable transaction analysis; - Customer-concentration discount; - Sensitivity analysis; - Expert opinions on fair value at closing. The central question will be: **What was NovaSense’s fair value to Asterix at the time of acquisition, considering the risks then known or knowable?** If an independent valuation supports a price near $190 million, the defense may survive on price. If the earlier forecast and customer-risk analysis support a materially lower value, the defense may fail on price as well. ### Likely fair-price result Fair price is the strongest defense fact, but it is not likely to be decisive alone. Because fair dealing is weak, the board must prove fair price with strong independent valuation evidence. The 70% write-down makes that harder. --- # 7. Potential liability of Elena, the committee members, other directors, and Peak ## A. Elena Elena is the most exposed defendant. ### Potential claims 1. **Breach of loyalty** - She stood on both sides of the transaction. - She received an undisclosed $8 million personal benefit. - She had a direct financial interest in the deal’s price and timing. 2. **Failure to disclose** - The $8 million side payment was material. - Her ownership and side interest were not fully disclosed. 3. **Breach of care** - She negotiated before the committee existed. - She publicly committed the company. - She pressured the committee with a competitive-threat narrative. 4. **Bad faith** - Concealing the side payment while advancing the transaction may support a conscious-disregard claim. - Using her position to shape the process before independent approval could support bad faith. ### Exculpation The exculpation clause does not protect loyalty violations, bad faith, or improper personal benefit. Elena’s $8 million side payment is an improper personal benefit. She is therefore exposed even if some of her conduct is framed as a duty-of-care failure. ### Likely exposure Elena could face: - Personal damages; - Disgorgement of the $8 million; - Fee-shifting exposure if appropriate; - Governance or injunctive relief; - Defense costs and possible indemnification limitations. ## B. Special committee members The committee members are less exposed than Elena, but not safe. ### Potential claims 1. **Duty of care** - Failure to review the earlier forecast; - Failure to obtain a sensitivity analysis; - Failure to conduct a broader market check; - Reliance on a conflicted adviser. 2. **Disclosure-related claims** - If they knew or should have known of the omitted facts and approved the proxy, they may face stronger claims. 3. **Bad faith** - If they consciously disregarded red flags, exculpation may not protect them. ### Independence The committee member with the charity tie is the most vulnerable. The others may not be personally tied to Elena, but they participated in a process that was compromised. ### Exculpation If the court finds that their failures were mere duty-of-care failures, the exculpation clause may bar monetary liability. But if the court finds bad faith or loyalty-related disclosure failures, exculpation may not protect them. ### Likely exposure - Possibly none for pure care failures; - Significant exposure if bad faith or knowing omissions are found; - D&O insurance will be important. ## C. Other directors The non-committee directors’ exposure depends on their role. If they: - Simply supported formation of the committee; - Relied on committee and adviser reports; - Did not personally participate in negotiating or disclosure; - And acted in good faith, their exposure is lower. Exculpation may protect them from duty-of-care claims. But if they: - Approved the proxy despite material omissions; - Ignored Peak’s conflict; - Failed to ensure the committee was truly independent; - Or ratified the process with awareness of material problems, they may face bad-faith exposure. The fact that six of the nine directors were originally nominated by Elena may make plaintiffs argue that the board was not sufficiently independent to provide a cleansing approval. But nomination alone does not make a director “interested” under the governing law unless there is a material personal benefit or both-sides position. ### Likely exposure - Moderate for passive directors if exculpation applies; - Higher for directors who participated in approval or disclosure; - Lower for directors with no personal benefit and good-faith reliance on independent process. ## D. Peak Partners Peak’s liability is the most uncertain but still meaningful. ### Potential aiding-and-abetting theory Peak may be liable if it **knowingly participated** in a fiduciary breach. Facts supporting that theory: - Peak earned $12 million from Elena and companies she controlled over five years. - Peak disclosed only a “historical relationship,” not the amount. - Peak advised the special committee on a transaction involving its prior client. - Peak’s range may have been based on projections that omitted the earlier lower forecast. - Peak did not appear to push for a customer-concentration sensitivity analysis. - The proxy did not disclose the amount of Peak’s prior fees. ### Hurdles for plaintiffs Plaintiffs must show that Peak knew of the fiduciary breach or knowingly participated in it. That is a higher bar than showing negligence. Peak could argue: - It disclosed its relationship generally; - It did not know about the $8 million side payment; - It provided a range within which the deal price fell; - The committee had ultimate authority; - It did not know the committee’s full data-room review process. But the $12 million prior fee relationship and nondisclosure of the amount are strong facts. ### Likely exposure Peak may face: - Aiding-and-abetting claims; - Contribution or indemnity claims by the company or directors; - Contractual or malpractice theories, depending on its engagement; - E&O insurance defenses. The company should preserve claims against Peak. --- # 8. Effect of the exculpation provision The exculpation provision eliminates monetary liability for **duty-of-care violations**, but not for: - Loyalty violations; - Bad faith; - Improper personal benefit. ## Effect on Elena For Elena, exculpation is of limited help. She likely received an improper personal benefit through the $8 million side payment. That alone takes her outside the exculpation clause. If the court finds loyalty or bad faith, exculpation will not protect her. If the clause covers officers, some pure care claims may be barred. If it does not cover officers, even some care claims may survive. But her main exposure is loyalty/improper benefit, which is not exculpated. ## Effect on directors For disinterested directors, exculpation may be powerful if their conduct is characterized as mere carelessness. Examples of protected conduct: - Failure to review the earlier forecast if done negligently; - Failure to obtain a sensitivity analysis if done negligently; - Failure to conduct a broader market check if done negligently; - Reasonable reliance on Peak, if the reliance was not bad-faith. But exculpation will not protect them if the court finds: - They knowingly approved material omissions; - They consciously disregarded Peak’s conflict; - They ignored red flags about customer concentration; - They participated in a loyalty breach; - They acted with improper personal benefit, if any. ## Effect on Peak Peak is not a director or officer and is not protected by the charter exculpation clause. ## Practical effect The exculpation clause likely narrows the directors’ monetary exposure for care failures, but it does not eliminate the case. The core claims will likely be framed as loyalty, disclosure, bad faith, or entire-fairness claims tied to the interested controller’s transaction. --- # 9. Likely outcome of a motion to dismiss and probable scope of discovery ## A. Motion to dismiss If the board moves to dismiss, the likely result is mixed. ### Claims likely to survive The following claims likely survive if properly pleaded: 1. **Entire fairness claims** against the board and Elena. 2. **Loyalty claims** against Elena for self-dealing and the side payment. 3. **Disclosure claims** based on the omitted material facts. 4. **Bad-faith claims** if plaintiffs can plead conscious disregard. 5. **Aiding-and-abetting claims** against Peak if they plead knowing participation. ### Claims likely to be dismissed or narrowed The following may be dismissed or narrowed: 1. **Pure duty-of-care claims** against disinterested directors, if the exculpation clause applies and no bad faith is adequately pleaded. 2. **Claims against directors** who were merely passive and had no personal benefit, if plaintiffs cannot plead more than negligence. 3. **Peak claims** if plaintiffs cannot plead that Peak knew of the fiduciary breach. ### Controller status at the motion stage If plaintiffs plead facts showing Elena’s 34% block, CEO/chair role, board nomination power, pre-commitment negotiations, public statements, and side payment, the court is unlikely to dismiss controller status at the pleading stage. Controller status is often a fact-intensive question better suited to discovery. ### Overall MTD outcome The board should expect: - Some dismissals or narrowing of care-based director claims; - Denial of dismissal on the central entire-fairness, loyalty, disclosure, and Peak aiding claims; - A case proceeding to discovery. ## B. Probable scope of discovery Discovery will likely be broad. Expect requests for: ### Controller and board composition - Voting agreements; - Proxy statements; - Board nomination history; - Elena’s voting history; - Communications showing influence over directors; - Board minutes and consents; - Executive compensation arrangements; - Founder agreements, if any. ### Special committee process - Committee charter; - Committee minutes; - Pre-committee negotiations; - Preliminary term sheet; - Communications between Elena and the committee; - Committee member independence questionnaires; - Charity contributions and foundation relationships; - Consideration of alternative targets; - Market check or lack thereof. ### Peak relationship and advice - Peak engagement letter; - Prior engagements with Elena; - Prior fees; - Conflict disclosures; - Peak valuation models; - Peak communications with the committee and Elena; - Peak review of projections and data room; - Peak’s sensitivity analyses, if any. ### Valuation and data room - NovaSense projections; - Earlier management forecast; - Data room index; - Management presentation materials; - Customer contracts; - Principal customer termination rights; - Revenue concentration reports; - Financial statements; - Sensitivity analyses; - DCF models; - Comparable transactions. ### Proxy and shareholder vote - Proxy statement drafts; - Disclosure committee materials; - Counsel memos; - Voting instructions; - Disinterested share calculations; - Vote tally; - Solicitation materials. ### Post-closing loss - Write-down analysis; - Customer termination documents; - Impairment calculations; - Integration decisions; - Post-closing performance; - Damages models. Expect expert discovery on valuation and damages. --- # 10. Available remedies and settlement exposure ## A. Available remedies The governing law lists: - Damages; - Rescission when practical; - Rescissory damages; - Fee shifting in appropriate circumstances; - Governance relief. ### Rescission Rescission is likely impractical. The transaction closed, nine months passed, and NovaSense’s largest customer terminated its contract. Unwinding the acquisition is unlikely to be practical. ### Rescissory damages The more likely remedy is rescissory damages: the difference between the price paid and the fair value of NovaSense at the time of acquisition. If the court finds fair value at closing was, for example, $140 million instead of $190 million, damages could be around $50 million, plus possibly lost value or disgorgement. The exact measure will depend on valuation evidence. ### Disgorgement Elena’s $8 million side payment is a likely disgorgement target. Even if the acquisition price was fair, she may still be required to disgorge the improper personal benefit. ### Fee shifting If the court finds appropriate misconduct, fee shifting may be available. That would increase exposure beyond direct damages. ### Governance relief The court may impose governance remedies, such as: - Independent board refreshment; - Independent committee protocols; - Related-party transaction controls; - Disclosure enhancements; - Clawback provisions. ## B. Settlement exposure The largest litigation number is the 70% write-down: approximately **$133 million**. But that is not automatically recoverable. Reasons the write-down may not translate fully into damages: - The customer termination risk was known or knowable before closing. - The acquisition may have been priced for growth. - A write-down is an accounting measurement, not a legal damages measure. - Fair value at closing may have been different from post-termination value. - Ordinary business risk is not automatically a fiduciary breach. However, the write-down is strong evidence that the risk was severe and may have been underpriced. ### Possible exposure categories 1. **Disgorgement of Elena’s side payment**: $8 million. 2. **Fair price differential**: unknown; could range from modest to very large. 3. **Fee shifting and costs**: depends on conduct and outcome. 4. **Litigation costs**: substantial, including valuation experts. ### Reasonable settlement range A realistic settlement range depends on valuation, but a plausible board-planning range is: - **High seven figures to low eight figures** if the court is likely to find some process unfairness but fair price is defensible; - **Mid eight figures** if valuation suggests moderate overpayment; - **Nine figures** if the valuation record shows the deal was substantially overpriced. The board should not plan around the full $133 million write-down, but it should take the write-down seriously as a valuation anchor. --- # 11. Whether the board should defend, seek early settlement, create an independent litigation committee, pursue claims against Peak, or take another course The board should not make these decisions as a whole board in its current composition, because the board is conflicted. It should form an **independent special litigation committee** first. ## Recommended immediate steps ### 1. Form an independent special litigation committee The committee should be composed of directors who are not: - Elena; - Current executives; - Directors with material financial ties to Elena; - Members of the original special committee if their independence is compromised. If there are not enough truly independent directors, the board should retain independent counsel and possibly independent advisers to direct the process. ### 2. Retain independent counsel The special litigation committee should retain its own outside counsel, separate from company counsel who advised the transaction. That counsel should: - Conduct a privileged investigation; - Assess controller status; - Evaluate committee independence; - Review Peak’s conflicts; - Identify all material omissions; - Assess bad-faith risk; - Coordinate with D&O insurers. ### 3. Issue a litigation hold Immediately preserve: - Board and committee materials; - Emails; - Data room; - Projections; - Peak work product; - Proxy drafts; - Customer contracts; - Communications about the transaction; - Post-closing write-down materials. ### 4. Notify D&O insurers Give notice of the claim and assess coverage, reservations, and consent-to-settle requirements. ### 5. Obtain an independent valuation The board should commission an independent valuation of NovaSense at the closing date, using: - The earlier lower forecast; - The principal customer termination risk; - Sensitivity analysis; - Comparable transactions; - DCF and probability-weighted methods. This is essential to decide whether to defend or settle. ## Should the board defend? A pure defensive posture is possible but high-risk. Reasons defense may be attractive: - $190 million was within Peak’s range; - A majority of disinterested shares voted in favor; - The transaction may not have been overpriced at closing; - The write-down may be partly ordinary business risk; - Some director care claims may be exculpated. Reasons defense is risky: - Entire fairness puts a heavy burden on defendants; - Fair dealing is weak; - Material omissions undermine the vote; - Peak was conflicted; - The committee was formed late; - The customer termination and write-down are damaging; - Elena’s side payment is difficult to defend; - Discovery will be broad and disruptive. The board should defend only if the independent valuation and investigation show that the price was fair and the process defects do not support bad faith. ## Should the board seek early settlement? Early settlement is likely the prudent path if the independent investigation confirms: - The side payment was material and undisclosed; - The proxy omissions were material; - Peak’s conflict was material; - Valuation supports a materially lower fair price; - Bad-faith risk is not clearly low. Settlement can cap exposure, avoid disruptive discovery, and preserve the company’s resources. It should be structured to: - Avoid admissions; - Include releases for directors where appropriate; - Preserve claims against Peak if warranted; - Address Elena’s side payment separately; - Coordinate with D&O insurance; - Include governance enhancements without conceding liability. A good settlement posture would be: “The board is resolving the claims to avoid costly and disruptive litigation, not because it concedes the merits.” ## Should the board pursue Peak? The special litigation committee should evaluate a claim against Peak. Reasons to pursue Peak: - It had a $12 million prior relationship with Elena; - It did not disclose the amount; - It advised a conflicted transaction; - It may have relied on incomplete projections; - A claim against Peak could offset company exposure; - Peak may have E&O insurance. Reasons to be cautious: - Aiding-and-abetting requires knowing participation; - Litigation against Peak may be costly; - Peak may not have deep recoverable assets; - A settlement with shareholders may release Peak unless structured carefully. Recommendation: Preserve claims against Peak, investigate, and use the claim as leverage if appropriate. Do not release Peak without independent litigation-committee approval. --- # 12. Governance changes that reduce future risk without unnecessarily conceding liability The board should implement governance reforms as voluntary enhancements, not as admissions of fault. ## A. Board composition and control - Increase the number of truly independent directors. - Consider separating the CEO and board chair roles or appointing an independent board chair. - Reduce reliance on founder nominees. - Establish an independent lead director role. - Clarify that the founder cannot unilaterally set deal terms before an independent committee is formed. ## B. Related-party transaction policy Adopt or strengthen a policy requiring that any transaction involving an interested director, officer, or controller be: - Referred to an independent committee before substantive negotiations; - Negotiated by independent directors; - Approved by an independent, fully empowered committee; - Conditioned on full disclosure; - Approved by an informed majority of disinterested shareholders where appropriate; - Reviewed by independent counsel; - Reviewed by an independent financial adviser with no material prior relationship. ## C. Conflict disclosure Require detailed conflict disclosures from: - Directors; - Officers; - Founder and controlling shareholders; - Family foundations; - Investment vehicles; - Financial advisers. Disclosures should include: - Ownership interests; - Side agreements; - Carried interest or performance fees; - Charity relationships; - Prior adviser fees; - Business relationships; - Family financial ties. ## D. Special committee protocols For future special committees: - Use only directors with no material financial ties to the interested party. - Select independent legal and financial advisers. - Require full conflict screening and fee-history disclosure. - Give the committee real authority to negotiate, delay, or reject. - Require a written committee charter. - Require contemporaneous minutes. - Require review of the entire data room, not just management-selected materials. - Require sensitivity analyses for material risks. - Require a market check or documented rationale for not conducting one. - Require a disclosure committee review before shareholder approval. ## E. Valuation and diligence controls For material acquisitions: - Require management to provide prior forecasts and explain changes. - Require sensitivity analysis for customer concentration. - Require probability-weighted valuation scenarios. - Require independent valuation support. - Require the committee to assess downside risks, not only base-case projections. - Require explicit treatment of key customer termination rights. ## F. Proxy and disclosure controls Before shareholder votes: - Use a disclosure committee. - Have independent counsel review materiality. - Disclose: - All side payments; - All material prior adviser fees; - All material changes in forecasts; - All material customer concentration risks; - All material committee independence issues. General statements such as “historical relationships” or “customer concentration” are not enough when the underlying facts are material. ## G. Clawback and improper-benefit controls Adopt or strengthen policies allowing the company to: - Claw back improper personal benefits; - Disgorge unauthorized transaction proceeds; - Recoup fiduciary gains; - Condition indemnification on good faith and absence of improper benefit. ## H. Oversight of controller influence If a founder or controller remains influential: - Require independent sign-off before public statements about pending transactions. - Prohibit preliminary term sheets before independent committee approval. - Limit the founder’s role in deal marketing. - Require independent verification of urgency claims. --- # Bottom-line recommendation The board should immediately: 1. **Create an independent special litigation committee.** 2. **Retain independent counsel and advisers.** 3. **Preserve all documents and data.** 4. **Conduct a privileged investigation of controller status, committee independence, Peak’s conflicts, omitted facts, and valuation.** 5. **Notify D&O insurers.** 6. **Obtain an independent valuation of NovaSense at closing.** 7. **Preserve claims against Peak.** 8. **Use the investigation to decide between defense and settlement.** Given the material omissions, compromised process, and entire-fairness standard, the board should take early settlement seriously. But the settlement decision should be made only after an independent investigation and valuation. The most defensible posture is: - Do not concede liability. - Do not allow Elena or conflicted directors to control the defense. - Investigate independently. - If valuation and disclosure facts are weak, settle early with a no-admission release structure. - If valuation is strong and bad-faith risk is low, defend, but remain prepared to settle to avoid disproportionate cost and disruption. - Implement governance reforms voluntarily to reduce future controller-transaction risk.